Biohaven Reports First Quarter 2021 Financial Results and Recent Business Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Biohaven Pharma (BHVN) Misses Q1 EPS by 15c, Revenues Beat
May 10, 2021 7:33 AM EDTBiohaven Pharma (NYSE: BHVN) reported Q1 EPS of ($2.97), $0.15 worse than the analyst estimate of ($2.82). Revenue for the quarter came in at $43.82 million versus the consensus estimate of $40.63 million.
Vlad Coric, M.D., Chief Executive Officer of Biohaven commented, "NURTEC ODT's performance, with its... More
